Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

被引：3

作者：

Agus, David B.

Stadler, Walter Michael

Shevrin, Daniel H.

Hart, Lowell

MacVicar, Gary R.

Hamid, Omid

Hainsworth, John D.

Gross, Mitchell E.

Wang, Jingyuan

Webb, Iain James

MacLean, David

Dreicer, Robert

机构：

[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] NorthShore Univ Hlth Syst, Evanston, IL USA

[4] Florida Canc Specialists, Ft Myers, FL USA

[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[6] Angeles Clin & Res Inst, Los Angeles, CA USA

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Univ So Calif, Westside Prostate Canc Ctr, Los Angeles, CA USA

[9] Millennium Pharmaceut Inc, Cambridge, MA USA

[10] Cleveland Clin, Cleveland, OH 44106 USA

来源：

关键词：

D O I：

10.1200/jco.2012.30.5_suppl.98

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1